Trials Sponsors Conditions Drugs Pricing

Conditions

HIV Infections

Keywords

HIV InfectionAcute HIV InfectionPrimary HIV InfectionAcute Seroconversion Syndrome

Outcome Measures

Primary Outcomes (1)

Participants are tested for HIV-1 RNA levels, the presence of antibodies to HIV antigens, and T cell subsets
first visit

Secondary Outcomes (1)

Data will be used for diagnostic, prognostic and management decisions as outlined by current HIV-1 Treatment
first visit

Study Arms (2)

high risk

Blood draw from individuals known to be or at high risk for HIV-infection

Other: blood draw

diagnosed

Blood draw f rom individuals diagnosed with HIV infection

Other: blood draw

Interventions

blood drawOther

* T cell subset enumeration * Serologic reactivity with HIV antigens * Viral load assays by bDNA, PCR, or RT-PCR * Routine Laboratory assessments (chemistries, liver function tests, hepatitis serology, RPR) * HIV-1 Resistance Testing

diagnosedhigh risk

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age16 Years+

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Subjects are either referred by primary health care providers, self-referred, or may be seeking enrollment in other ADARC clinical trials in the NYC area.

You may qualify if:

recently infected with HIV-1 HIV-1 negative, and at high risk for infection

Sponsors & Collaborators

Rockefeller University
Otherlead

Study Sites (2)

Aaron Diamond AIDS Research Center (ADARC)

New York, New York, 10016, United States

Rockefeller University Hospital

New York, New York, 10021, United States

Biospecimen

Retention: SAMPLES WITH DNA

whole blood

MeSH Terms

Conditions

HIV Infections

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency Syndromes

Study Officials

Martin M Markowitz, MD
Rockefeller University
PRINCIPAL INVESTIGATOR

Enrollment

600 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: OTHER
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

September 20, 2005

First Posted

September 22, 2005

Study Start

July 2000

Date type not reported

This date has not been verified as actual or estimated.

Study Stopped

Viral and Host Factors in the Transmission and Pathogenesis of HIV

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (2)

high risk

diagnosed

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

Related Links

Biospecimen

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (2)

high risk

diagnosed

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

Related Links

Biospecimen

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Data Sharing

Source record

Locations